Clinical Scorecard: Prescription Trends of Leucovorin for Pediatric Patients Diagnosed with Autism Spectrum Disorder
At a Glance
Category
Detail
Condition
Key Mechanisms
Leucovorin (folinic acid) is a biologically active form of folic acid that may improve verbal communication in folate-deficient children, but it is not FDA-approved for ASD.
Target Population
Care Setting
Key Highlights
No large-scale studies confirm the safety and efficacy of leucovorin for ASD, despite rising prescription rates.
Guideline-Based Recommendations
Diagnosis
Management
Monitor leucovorin prescriptions and consider patient-specific factors.
Exercise caution in prescribing due to lack of evidence for ASD.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
838,801 patients with ASD contributing to 11,913,139 outpatient encounters.
Increased leucovorin prescriptions noted following media attention and public announcements.
Clinical Best Practices
Ensure thorough assessment of patient eligibility for leucovorin treatment.
Stay informed about ongoing research and regulatory updates regarding leucovorin.
